Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DANYELZA vs EMPLICITI
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Disialoganglioside GD2-binding monoclonal antibody that induces antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity against GD2-positive tumor cells.
Elotuzumab is a humanized monoclonal antibody that targets the SLAMF7 (signaling lymphocytic activation molecule F7) receptor expressed on myeloma cells and natural killer (NK) cells. It enhances NK cell-mediated antibody-dependent cellular cytotoxicity (ADCC) via direct activation of NK cells through SLAMF7 and CD16 engagement, and also directly activates NK cells to induce killing of myeloma cells.
Neuroblastoma: in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2), and retinoic acid for treatment of pediatric patients with high-risk neuroblastoma who have achieved at least a partial response to prior first-line multiagent, multimodality therapy.
FDA-approved: In combination with lenalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received one to three prior therapies,FDA-approved: In combination with pomalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor
1.5 m Ci/kg (0.037 MBq/kg) intravenously over 30 minutes on days 1, 3, and 5 of each 28-day cycle.
10 mg/kg IV weekly for first 8 weeks, then every 2 weeks thereafter; administer with lenalidomide and dexamethasone.
Terminal elimination half-life is approximately 29 days (range 25–35 days) at steady state, supporting a weekly dosing schedule for maintaining therapeutic concentrations.
Terminal elimination half-life is approximately 26-29 days. This long half-life supports biweekly IV dosing after initial weekly schedule.
Metabolized via catabolic pathways into small peptides and amino acids; no major CYP450 involvement.
Elotuzumab is a monoclonal antibody; metabolism involves catabolism via proteolytic degradation into small peptides and amino acids. No specific CYP450 enzyme involvement.
Renal elimination accounts for approximately 80% of the administered dose as unchanged drug; the remaining 20% is excreted via the biliary/fecal route.
Empliciti (elotuzumab) is a monoclonal antibody; elimination occurs via intracellular catabolism, yielding amino acids. Renal excretion of intact drug is negligible (<1%). Biliary/fecal excretion is minimal; no specific data on percentage.
Approximately 99% bound to plasma proteins, primarily albumin and low-density lipoproteins.
Elotuzumab is a monoclonal antibody; protein binding is not clinically meaningful. Typically, monoclonal antibodies have negligible binding to plasma proteins other than target antigen.
Volume of distribution is approximately 0.2 L/kg, indicating limited extravascular distribution and confinement primarily to the plasma compartment.
Volume of distribution is approximately 5-7 L (or ~0.07 L/kg for a 70 kg patient), indicating distribution primarily in the vascular space.
Only available as intravenous formulation; bioavailability is 100% by definition for IV administration, with no oral or other route available.
Empliciti is administered intravenously, thus bioavailability is 100% by IV route. No other routes are approved.
No dose adjustment recommended for mild to moderate renal impairment. Severe renal impairment or end-stage renal disease: not studied, use with caution.
No dose adjustment required for mild to moderate renal impairment (Cr Cl ≥30 m L/min). Not studied in severe renal impairment (Cr Cl <30 m L/min) or dialysis.
No dose adjustment recommended for mild to moderate hepatic impairment (Child-Pugh A or B). Severe hepatic impairment (Child-Pugh C): not studied, use with caution.
No formal studies in hepatic impairment. Use caution in patients with moderate to severe hepatic impairment (Child-Pugh B or C) as exposure may be increased.
Safety and efficacy not established in pediatric patients.
Safety and efficacy not established in pediatric patients.
No specific dose adjustment recommended; monitor for toxicity due to potential age-related renal or hepatic impairment.
No specific dose adjustment required; monitor for toxicity due to age-related comorbidities and potential decreased organ function.
WARNING: SERIOUS INFUSION-RELATED REACTIONS AND NEUROTOXICITY. Premedicate for infusion-related reactions. Monitor for and manage neurotoxicity (severe neuropathic pain, transverse myelitis, posterior reversible encephalopathy syndrome).
None
Infusion-related reactions (hypotension, urticaria, bronchospasm); neurotoxicity (severe pain, transverse myelitis, PRES); myelosuppression; capillary leak syndrome; infections; electrolyte abnormalities; fever; hypersensitivity reactions; interference with tumor response assessment.
Infusion reactions: Premedicate with acetaminophen, H1 and H2 blockers, and corticosteroids; monitor during infusion; may require interruption or discontinuation,Infections: Increased risk, especially with lymphopenia; monitor for signs and manage promptly,Second primary malignancies: Observed in clinical trials; consider risk,Hepatotoxicity: Elevations in liver enzymes; monitor hepatic function,Interference with serum protein electrophoresis and immunofixation assays: Elotuzumab may produce a band that interferes with detection of M-protein; monitor using alternative methods
None known.
History of severe hypersensitivity reactions to elotuzumab or any of its excipients
No specific food interactions are established for DANYELZA. Maintain adequate hydration and nutrition as tolerated. Avoid grapefruit and grapefruit juice if taking concomitant medications that are CYP3A4 substrates, though DANYELZA itself is not metabolized by CYP450 enzymes.
No specific food interactions with Empliciti have been identified. However, when used in combination with lenalidomide and dexamethasone, patients should avoid grapefruit and grapefruit juice due to potential interaction with lenalidomide metabolism (CYP3A4). Maintain adequate hydration and nutrition as tolerated.
Based on its mechanism of action (GD2-directed antibody), DANYELZA may cause fetal harm. There are no adequate human data. In animal studies, administration resulted in embryofetal toxicity including malformations and growth retardation. Advise females of reproductive potential of the potential risk to a fetus. Use effective contraception during treatment and for at least 2 months after the last dose.
Pregnancy Category N (not classified). Empliciti (elotuzumab) is a monoclonal antibody. Ig G molecules cross the placenta, with increasing transfer in the second and third trimesters. Based on its mechanism of action (SLAMF7-directed immunostimulatory), there is potential for fetal harm including B-cell depletion and immune alterations. No adequate human data; animal studies have not been conducted. Avoid use during pregnancy unless benefit outweighs risk.
No data on presence in human milk, effects on breastfed infant, or effects on milk production. Because of the potential for serious adverse reactions, advise women not to breastfeed during treatment and for at least 2 months after the last dose.
No data on presence in human milk, effects on breastfed infant, or milk production. Human Ig G is excreted in breast milk but not systemically absorbed in significant amounts. M/P ratio unknown. Consider developmental and health benefits of breastfeeding along with maternal need for therapy and potential adverse effects on infant (B-cell depletion).
Dosing adjustments during pregnancy are not established. Use only if potential benefit justifies potential risk to the fetus. Consider delaying treatment until after delivery if feasible.
No pharmacokinetic data in pregnancy. Monoclonal antibodies may have altered clearance due to increased plasma volume. However, no recommended dose adjustment; use with caution. No specific guidelines for dose modification during pregnancy.
DANYELZA (naxitamab) is a GD2-binding monoclonal antibody for relapsed/refractory high-risk neuroblastoma. Premedicate with antihistamines, acetaminophen, and corticosteroids to mitigate infusion-related reactions. Monitor for severe pain, which is a known adverse effect; may require opioid analgesics. Closely monitor for hypotension and bronchospasm during infusion. Administer in a setting equipped to manage anaphylaxis.
Empliciti (elotuzumab) is an immunostimulatory monoclonal antibody used in combination with lenalidomide and dexamethasone for relapsed/refractory multiple myeloma. Premedicate with diphenhydramine, acetaminophen, and H2 blocker to mitigate infusion reactions (IRs). Monitor for IRs, notably hypotension, bronchospasm, and urticaria, especially during the first dose. Administer corticosteroids prior to empliciti infusion to reduce IR risk. Do not administer as an intravenous push or bolus; use a controlled intravenous infusion. If a dose is missed, administer as soon as possible; do not wait until the next scheduled dose. Empliciti carries a boxed warning for increased mortality when used with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma who are not candidates for transplant. Advise patients of potential teratogenicity with lenalidomide and dexamethasone; ensure pregnancy prevention.
DANYELZA is given intravenously over several hours, typically on consecutive days.,You may experience severe pain during or after infusion; report it immediately.,Common side effects include fever, nausea, vomiting, and low blood pressure.,Serious allergic reactions can occur; inform your doctor if you develop hives, trouble breathing, or swelling.,Avoid driving or operating machinery if you feel dizzy or tired after treatment.,Notify your healthcare provider of all medications you are taking, including over-the-counter drugs and supplements.
You will receive Empliciti as an intravenous infusion over several hours, and you will be monitored for infusion reactions such as chills, fever, difficulty breathing, or rash.,Before each infusion, you will receive medicines to reduce the risk of infusion reactions, including acetaminophen, an antihistamine, and a corticosteroid.,If you miss an appointment, contact your healthcare provider immediately to reschedule; do not wait until the next scheduled dose.,Empliciti may cause serious infections; report any signs of infection such as fever, cough, or pain.,Avoid pregnancy while on Empliciti combination therapy; use effective contraception and discuss appropriate methods with your doctor.,You may experience fatigue, diarrhea, constipation, or nerve pain; inform your doctor if these become bothersome.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DANYELZA vs EMPLICITI, answered by our medical review team.
DANYELZA is a Monoclonal Antibody Antineoplastic that works by Disialoganglioside GD2-binding monoclonal antibody that induces antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity against GD2-positive tumor cells.. EMPLICITI is a Monoclonal Antibody Antineoplastic that works by Elotuzumab is a humanized monoclonal antibody that targets the SLAMF7 (signaling lymphocytic activation molecule F7) receptor expressed on myeloma cells and natural killer (NK) cells. It enhances NK cell-mediated antibody-dependent cellular cytotoxicity (ADCC) via direct activation of NK cells through SLAMF7 and CD16 engagement, and also directly activates NK cells to induce killing of myeloma cells.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DANYELZA and EMPLICITI depend on the specific clinical indication. These are both Monoclonal Antibody Antineoplastic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DANYELZA is: 1.5 m Ci/kg (0.037 MBq/kg) intravenously over 30 minutes on days 1, 3, and 5 of each 28-day cycle.. The standard adult dose of EMPLICITI is: 10 mg/kg IV weekly for first 8 weeks, then every 2 weeks thereafter; administer with lenalidomide and dexamethasone.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between DANYELZA and EMPLICITI in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. DANYELZA is classified as Category C. Based on its mechanism of action (GD2-directed antibody), DANYELZA may cause fetal harm. There are no adequate human data. In animal studies, administration resulted in embryofetal. EMPLICITI is classified as Category C. Pregnancy Category N (not classified). Empliciti (elotuzumab) is a monoclonal antibody. IgG molecules cross the placenta, with increasing transfer in the second and third trimester. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.